ENTITY
BeiGene

BeiGene (6160 HK)

309
Analysis
Health CareChina
BeiGene, Ltd. operates as a commercial stage biopharmaceutical company. The Company focuses on discovery, development, and commercialization of molecularly targeted and immuno-oncology drugs for the treatment of cancer. BeiGene serves patients worldwide.
more
Refresh
bullishTencent Music
06 Oct 2018 16:18

Last Week in GER Research: Tencent Music Vs. Spotify, Ganfeng Lithium, Meituan, Weidai, and Innovent

Below is a recap of the key IPO research produced by the Global Equity Research team. This week we highlight why we think Tencent Music...

Logo
406 Views
Share
02 Oct 2018 06:24

Innovent Biologics IPO Preview: Limited Upside on China's PD-1 Drug Market Compared to BeiGene

Innovent Biologics Inc (1641475D HK) is the fourth pre-profit biotech firm to IPO in Hong Kong since Ascletis Pharma Inc (1672 HK), BeiGene Ltd...

Logo
691 Views
Share
02 Oct 2018 06:08

Last Week in GER Research: Haidilao, Popflops, Bitmain, Shandong Gold, Niu and China Renaissance

Below is a recap of the key IPO research produced by the Global Equity Research team. This week we highlight 25% potential downside at Haidilao as...

Logo
391 Views
Share
bearishMeituan
24 Sep 2018 06:21

Last Week in GER Research: Meituan, IPO Trading Strategy, Shandong Gold, Maoyan and Viomi

Below is a recap of the key IPO research produced by the Global Equity Research team. This week we highlight that Meituan is closer to fair value...

Logo
332 Views
Share
bearishMeituan
17 Sep 2018 06:37

Last Week in GER Research: Meituan, Nio, Haidilao, Shandong Gold, China Renais., X Financial and PDD

Below is a recap of the key IPO research produced by the Global Equity Research team. This week we dig into the economics of Mobike as it relates...

Logo
365 Views
Share
x